Philippe Thiry
6 Papers
65 Citations
Philippe Thiry is an academic researcher. The author has contributed to research in topics: Lung transplantation & Population. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies
Franck Saint-Marcoux,Christiane Knoop,Jean Debord,Philippe Thiry,Annick Rousseau,Marc Estenne,Pierre Marquet +6 more
TL;DR: The one-compartment model with first-order elimination convoluted with a double gamma distribution gave the best results in both CF and non-CF lung transplant recipients and MAP-BE allowing tacrolimus therapeutic drug monitoring based on AUC12 were developed.
64
Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions.
Christiane Knoop,Philippe Thiry,Franck Saint-Marcoux,Annick Rousseau,Pierre Marquet,Marc Estenne +5 more
TL;DR: Patients with CF have a higher tacrolimus oral clearance, but nonsignificant differences in short‐term inter‐ and intrasubject variability of exposure compared to patients without CF.
44
Patient Characteristics Influencing Ciclosporin Pharmacokinetics and Accurate Bayesian Estimation of Ciclosporin Exposure in Heart, Lung and Kidney Transplant Patients
Franck Saint-Marcoux,Pierre Marquet,Evelyne Jacqz-Aigrain,Nicole Bernard,Philippe Thiry,Yann Le Meur,Annick Rousseau +6 more
TL;DR: The design of a new pharmacokinetic model for ciclosporin microemulsion in allograft transplants resulted in the design of an accurate MAP-BE based on three blood concentrations and these covariates, and the identification of significant covariates.
43
Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions.
Christiane Knoop,Ingrid Vervier,Philippe Thiry,Marc De Backer,John M. Kovarik,Annick Rousseau,Pierre Marquet,Marc Estenne +7 more
TL;DR: Compared to patients without CF, patients with CF show a lower bioavailability of CsA and a greater intrasubject variability of Cmax, C2, and AUC, while C2 is the best single-point predictor of the AUC0–4 in lung transplant recipients with and without CF.
36
Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis
Annick Rousseau,Caroline Monchaud,Jean Debord,Ingrid Vervier,Marc Estenne,Philippe Thiry,Pierre Marquet +6 more
TL;DR: This study demonstrated the applicability and good performance of the PK model previously developed for oral cyclosporin and of the MAP Bayesian estimation of cyclosPORin systemic exposure in CF and non-CF patients and proposed a monitoring tool specifically designed for cyclospora monitoring in patients with CF.
29